Neurocrine Biosciences

Last updated
Neurocrine Biosciences, Inc.
Company type Public
Industry Biotechnology
Founded1992;32 years ago (1992)
Headquarters San Diego, California, U.S.
Key people
 William Rastetter (chairman)
Kevin C. Gorman (CEO)
RevenueIncrease2.svg US$788 million (2019)
Number of employees
1,350 (June 30, 2023)
Website neurocrine.com
Footnotes /references
[1] [2]

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. [1] It is headquartered in San Diego, California, and led by CEO Kevin Gorman. [3] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). [4]

Contents

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia [5] and with a partner for endometriosis and uterine fibroids. [6]

History

Previous logo.svg Neurocrine Biosciences historic logo.svg
Previous logo.svg

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, [7] and Lawrence Steinman of Stanford University. [8] [9] The company was backed by Avalon Ventures among others. [8]

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. [10] The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million. [11]

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors. [12]

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million. [13]

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. [14] [15] The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. [16] In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. [17] Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. [18] The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan. [19]

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors. [20]

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) [21] worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. [22] The deal paid Neurocrine $75 million up front. [23]

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. [24] Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome. [25]

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales. [5] [26]

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. [27] [28] In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. [29] The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development. [6]

In 2021,Nexera Pharma  [ ja ]in Japan licensed out its investigational schizophrenia drug,NBI-1117568 , to Neurocrine Biosciences for development. [30]

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . [31] [32] [33] The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. [34] As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results. [35]

Product pipeline

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

INSIGHTEC Ltd., is an Israeli privately held medical device company that sells MR guided Focused Ultrasound equipment. The technology can destroy deep tissue in the body without the need for incisions.

<span class="mw-page-title-main">Gonadotropin-releasing hormone antagonist</span> Class of medications

Gonadotropin-releasing hormone antagonists are a class of medications that antagonize the gonadotropin-releasing hormone receptor and thus the action of gonadotropin-releasing hormone (GnRH). They are used in the treatment of prostate cancer, endometriosis, uterine fibroids, female infertility in assisted reproduction, and for other indications.

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is a nonprofit organization, based in Connecticut, aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Veliparib</span> Chemical compound

Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.

<span class="mw-page-title-main">Ulipristal acetate</span> Chemical compound

Ulipristal acetate, sold under the brand name Ella among others, is a medication used for emergency contraception and uterine fibroids. As emergency contraception it should be used within 120 hours of vaginally penetrating intercourse. For fibroids it may be taken for up to six months. It is taken by mouth.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Elagolix</span> Chemical compound

Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of pain associated with endometriosis in women. It is also under development for the treatment of uterine fibroids and heavy menstrual bleeding in women. The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men as well, but development for these conditions was discontinued. Elagolix is taken by mouth once or twice per day. It can be taken for up to 6 to 24 months, depending on the dosage.

<span class="mw-page-title-main">Relugolix</span> Chemical compound

Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is taken by mouth.

<span class="mw-page-title-main">Venetoclax</span> Medication

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).

<span class="mw-page-title-main">Valbenazine</span> Chemical compound

Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.

<span class="mw-page-title-main">Opicapone</span> Chemical compound

Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.

<span class="mw-page-title-main">Linzagolix</span> Chemical compound

Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids. Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist developed by Kissei Pharmaceutical and ObsEva.

Elagolix/estradiol/norethisterone acetate, sold under the brand name Oriahnn, is a fixed-dose combination medication used to treat heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It contains elagolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethisterone acetate, a progestin. It is taken by mouth. Oriahnn is co-packaged as a combination of elagolix/estradiol/norethisterone acetate capsules with elagolix capsules.

BeiGene, Ltd. is a China-based drug developer. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

NBI-1117568 is an investigational antipsychotic drug for schizophrenia that was out-licensed Nexera Pharma in to Neurocrine Biosciences, a United States-based pharmaceutical company. It is administered orally.

References

  1. 1 2 "Company Overview of Neurocrine Biosciences, Inc". Bloomberg Business. Retrieved May 13, 2018.
  2. ↑ "Neurocrine Biosciences Revenue 2006-2021 | NBIX".
  3. ↑ Adams, Ben (August 30, 2016). "Neurocrine Submits Valbenazine NDA Early, Set For 2017 Approval". FierceBiotech. Retrieved May 13, 2017.
  4. ↑ "FDA Approves New Strength for Tardive Dyskinesia Drug". Pharmacy Times. October 6, 2017. Retrieved May 13, 2018.
  5. 1 2 3 "Neurocrine Nabs BIAL's PD Therapy Opicapone for North America". Genetic Engineering & Biotechnology News. February 10, 2017. Retrieved May 13, 2018.
  6. 1 2 3 Inacio, Patricia (November 13, 2017). "Elagolix Improves Uterine Fibroid Symptoms With and Without Add-Back Therapy, Trials Show". Endometriosis News. Retrieved May 13, 2018.
  7. ↑ "Wylie Vale". SALK. January 6, 2012.
  8. 1 2 Veggeberg, Scott (April 5, 1993). "Betting on Biotech". The Scientist.
  9. ↑ "Executive Profile Lawrence Steinman". Bloomberg. Retrieved June 5, 2018.
  10. ↑ "Company Briefs". The New York Times. February 17, 1995.
  11. ↑ "Neorocrine Biosciences Raises $34.2 mm in IPO of 3.5mm Shares". Scrip Pharma Intelligence. May 1996.
  12. ↑ "Lilly Paying for Obesity and Alzheimer Study". The New York Times. October 22, 1996.
  13. ↑ "Neurocrine Biosciences and GlaxoSmithKline Announce Worldwide Collaboration For CRF Receptor Antagonists INcluding the Phase I Compound NBI-34041". Evaluate Group. July 24, 2001.
  14. ↑ Chartrand, Sabra (June 17, 2002). "Patents; An Insomnia Drug, Based on a Patented Chemical Compound, Also Receives Protection". The New York Times.
  15. ↑ Crabtree, Penni (March 23, 2004). "Helping People to Sleep Could Earn Neurocrine Big Bucks". San Diego Union Tribune.
  16. ↑ "Company News; Pfizer is Buying Rights to Experimental Insomnia Drug". The New York Times. December 20, 2002.
  17. ↑ "Pfizer Dumps Neurocrine, Shares Plunge". Forbes. June 22, 2006.
  18. ↑ "Neurocrine Receives Approvable Letter for Indiplon Capsules With Additional Safety and Efficacy Data Required by FDA". Drugs.com. December 13, 2007.
  19. ↑ "Neurocrine Biosciences and Dainippon Sumitomo Pharma Announce Agreement to Develop and Commercialize Indiplon in Japan". Reuters. November 1, 2007.
  20. ↑ "Neurocrine Biosciences, Inc. Says CEO to Step Down". BioSpace. January 15, 2008.
  21. ↑ Carroll, John (January 7, 2014). "Neurocrine Shares Soar with a Promising Second Take on a PhIIb Drug". FierceBiotech.
  22. ↑ Gellene, Denise (June 16, 2010). "Neurocrine Inks Deal with Abbot". Xconomy.
  23. ↑ "Abbot and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolic for the Treatment of Endometriosis". FierceBiotech. June 16, 2010.
  24. ↑ Al Idrus, Amirah (January 2, 2018). "After Disappointing 2016, New Drug Approvals Roared Back to Life in 2017". FierceBiotech.
  25. ↑ "Brief-Neurocrine Granted FDA Orphan Drug Designation for Valbenazine". Reuters. October 23, 2017.
  26. ↑ "Brief-Neurocrine and Bial Reports Exclusive North American Licensing Agreement for Opicapone". Reuters. February 9, 2017.
  27. ↑ Melao, Alice (September 7, 2017). "AbbVie Files for FDA Approval of Elagolix to Treat Endometriosis-associated Pain". Endometriosis News.
  28. ↑ Moore, Charles (August 25, 2016). "Endometriosis Therapy Candidate Elagolix Meeting Phase 3 Clinical Trial Primary Targets". Endometriosis News. Retrieved 14 October 2016.
  29. ↑ "AbbVie : FDA moves the goal line on AbbVie's endometriosis drug elagolix". 4-traders. April 11, 2018.
  30. ↑ "ニューロクライン社との統合失調症およびその他の精神神経疾患を対象とした新規ムスカリン受容体作動薬に関するライセンス契約締結のお知らせ". プレスリリース・ニュースリリース配信シェアNo.1｜PR TIMES. PR TIMES. 2021-11-22. Retrieved 2024-09-17.
  31. 1 2 日経バイオテクONLINE (2024-09-02). "ネクセラファーマ、統合失調症治療薬候補 NBI-1117568の第II相臨床試験の良好な結果によりニューロクライン社より35百万米ドルのマイルストンを受領". 日経バイオテクONLINE. 日本経済新聞社. Retrieved 2024-09-17.
  32. 1 2 "ネクセラ---大幅反落、ニューロクラインの株価下落に追随売り | 個別株 - 株探ニュース". kabutan.jp. MINKABU THE INFONOID, Inc. 2024-08-29. Retrieved 2024-09-17.
  33. 1 2 Priyan, Vishnu (2024-08-29). "Neurocrine reports positive data from Phase II schizophrenia treatment trial". Clinical Trials Arena. Retrieved 2024-09-21.
  34. ↑ "Nxera Pharma Official IR Blog　「ニューロクライン社から35百万米ドルのマイルストン受領」". soseiheptares.blogspot.com. ネクセラファーマ. 2024-09-02. Retrieved 2024-09-19.
  35. ↑ "Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results". Zacks Investment Research. Zacks Investment. 2024-08-29. Retrieved 2024-09-17.
  36. ↑ "NBI-74788". Biocentury. Retrieved May 13, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.